Literature DB >> 28668872

Impact and Prediction of Lymph Node Involvement in Patients with Intrahepatic Cholangiocarcinoma After Curative Resection.

Noboru Harada1, Tomoharu Yoshizumi2, Yo-Ichi Yamashita3, Yuji Soejima2, Toru Ikegami2, Norifumi Harimoto2, Shinji Itoh2, Yoshihiko Maehara2.   

Abstract

BACKGROUND: The aim of this study was to identify the preoperative predictors of prognosis in patients with intrahepatic cholangiocarcinoma (ICC) undergoing resection. PATIENTS AND METHODS: We enrolled 90 patients with ICC who underwent surgical resection, including 59 in whom surgery was considered curative, and measured the overall survival (OS), recurrence-free survival (RFS), and other outcomes and potential prognostic factors.
RESULTS: Multivariate Cox proportional hazards analysis showed that tumor in the resection margins (R>0) independently predicted long-term OS in the whole cohort. In the curatively-resected group (R0), lymph node involvement was the only independent predictor of long-term OS. Multiple tumors, perihilar tumor location and serum carcinoembryonic antigen (CEA) concentration >2.2 ng/ml were independent predictors of lymph node involvement before curative resection.
CONCLUSION: Patients with ICC with multiple tumors, perihilar tumors and serum CEA concentration >2.2 ng/ml in association with lymph node involvement may need additional preoperative chemotherapy. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Lymph node metastasis; R0 resection; perihilar

Mesh:

Substances:

Year:  2017        PMID: 28668872     DOI: 10.21873/anticanres.11751

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  C-reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma.

Authors:  T Matsumoto; S Itoh; T Yoshizumi; T Kurihara; S Yoshiya; Y Mano; K Takeishi; N Harada; T Ikegami; Y Soejima; H Baba; M Mori
Journal:  BJS Open       Date:  2020-09-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.